Publications
- Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial2015 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry2015 | First Faculty of Medicine
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study2015 | First Faculty of Medicine
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial2015 | Publication without faculty affiliation
- Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines2014 | First Faculty of Medicine, Second Faculty of Medicine
- Denosumab - a new potential effect of RANKL inhibitor2014 | Second Faculty of Medicine
- Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression2013 | First Faculty of Medicine, Second Faculty of Medicine
- VEGFREverolimus in the treatment of metastatic renal cell carcinoma - subanalysis of patients from the RECORD-1 study pretreated with one vs. two VEGFR inhibitors2012 | Second Faculty of Medicine
- NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristcs of human mammary tumors2009 | First Faculty of Medicine, Second Faculty of Medicine
- Preoperative radiotherapy for locally advanced rectal cancer and prognostic factors influencing outcome2006 | Second Faculty of Medicine
Loading network view...
